Pfizer announced that the European Commission has approved Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for active immunization for the prevention of vaccine-type invasive disease ococcus pneumoniae in adults aged 50 years and older. Emilio Emini, Ph.D., chief scientific officer, Vaccine Research, Pfizer Inc., said, “Prevenar 13, the first and only pneumococcal conjugate vaccine approved by the European Commission for use in adults, has the potential to prevent invasive pneumococcal disease in adults aged 50 and older – a time of life when the risk for contracting the disease begins to increase. It is important that older adults talk to their health care provider about pneumococcal disease prevention and Prevenar 13 as part of a plan for healthy aging.” http://www.businesswire.com/news/home/20111027005499/en/Pfizer-Receives-European-Approval-Extend-Prevenar-13